Study S002366

Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06779929
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 70000
Start: 2024-11-01
Primary completion: 2025-12-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Type 2 Diabetes
Interventions: DRUG:Tirzepatide; DRUG:Dulaglutide; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Composite CV outcome [From treatment initiation to end of follow up, up to 48 months.]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005386	Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. Ostrominski JW, Diabetes care	2026	Nonrandomized study	PMID 41778928 DOI	registry reference RESULT:41778928
R0008169	Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Nicholls SJ, American heart journal	2024	Protocol	PMID 37758044 DOI	registry reference BACKGROUND:37758044